BNTC (Benitec Biopharma) EBITDA Margin %: 0.00% (As of Mar. 2026)

What is Benitec Biopharma EBITDA Margin %?

Benitec Biopharma BNTC -5.01% 34 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates BNTC with a GF Score™ of 34/100. Among 945 Biotechnology companies, Benitec Biopharma ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Benitec Biopharma's EBITDA for the three months ended in Mar. 2026 was $-13.46 Mil. Benitec Biopharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Benitec Biopharma's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Benitec Biopharma (NAS:BNTC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Benitec Biopharma EBITDA Margin % Related Terms

Benitec Biopharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma EBITDA Margin % Chart

Benitec Biopharma Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EBITDA Margin %

Get a 7-Day Free Trial

-22,800.00

-24,361.64

-24,933.33

0.00

Benitec Biopharma Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBITDA Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

BNTC vs OABI, FBRX, LXEO: EBITDA Margin % Comparison

For the Biotechnology subindustry, Benitec Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benitec Biopharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's EBITDA Margin % falls into.

Save Embed

34GF Score

Benitec Biopharma Inc BNTC

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Benitec Biopharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Benitec Biopharma's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2025 )	/	Revenue (A: Jun. 2025 )
	=	-41.369	/	0
	=	%

Benitec Biopharma's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-13.463	/	0
	=	%

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of 0.00% mean?

Benitec Biopharma (BNTC) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Benitec Biopharma and its competitors. According to the industry distribution chart, Benitec Biopharma ranks #999999 out of 945 companies in the Biotechnology industry.

Is Benitec Biopharma's EBITDA Margin % too high?

Benitec Biopharma's current EBITDA Margin % is 0.00%. Based on the distribution chart, Benitec Biopharma ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.

How does Benitec Biopharma's EBITDA Margin % compare to OABI and FBRX?

According to the Biotechnology industry distribution chart, Benitec Biopharma ranks #999999 out of 945 companies for EBITDA Margin %. This places Benitec Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Benitec Biopharma and its competitors. Benitec Biopharma's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Benitec Biopharma stock overvalued right now?

Benitec Biopharma (BNTC) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Industry Healthcare Biotechnology

Comparable Companies OABI FBRX LXEO VNDA LYEL XFOR ARTV ZURA ENTA VSTM VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 3940 Trust Way, Hayward, CA, USA, 94545

Website https://www.benitec.com

Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.

34GF Score

Get the complete analysis for BNTC

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.00

Price

View BNTC Analysis

See EBITDA Margin % data for all stocks →